Biotech Values

[biocqr]

Scynexis (SCYX) has the only commercial trial for Candida Auris on ClinicalTrials.gov. Interim data to be presented April 13...

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Candidiasis Caused by Candida Auris (CARES) (CARES)

https://clinicaltrials.gov/ct2/show/NCT03363841?cond=Candida+Auris&rank=1

SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study

https://www.prnewswire.com/news-releases/scynexiss-ibrexafungerp-shows-favorable-clinical-activity-in-resistant-fungal-infections-including-candida-auris-cases-from-the-cares-study-in-data-to-be-presented-at-the-29th-eccmid-300823802.html

Six presentations will provide additional evidence of the potent and broad antifungal activity of oral ibrexafungerp, including new clinical case studies from the CARES and FURI trials as well as promising preclinical data

Case studies from the CARES trial, the first study of an investigational agent to treat patients with Candida auris infections, show favorable outcomes following treatment with oral ibrexafungerp